Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 12:12:5713-5720.
doi: 10.2147/CMAR.S242781. eCollection 2020.

LncRNA PLAC2 Positively Regulates CDK2 to Promote Ovarian Carcinoma Cell Proliferation

Yuanqi He  1 , Liqun Wei  1 , Shihong Zhang  1   2 , Haining Liu  1 , Fang Fang  1 , Yue Li  1
Affiliations

LncRNA PLAC2 Positively Regulates CDK2 to Promote Ovarian Carcinoma Cell Proliferation

Yuanqi He et al. Cancer Manag Res. .

Abstract

Background: PLAC2 has been reported to participate in glioma, but its role in ovarian carcinoma (OC) is unclear. This study investigated the role of lncRNA PLAC2 in OC.

Methods: A 5-year follow-up study of 64 patients was carried out in Weihai Municipal Hospital after the admission of patients. A total of 64 OC patients were selected from 178 OC patients admitted in the aforementioned hospital from August 2011 to January 2014. Cell transfections, cell cycle analysis, cell proliferation assay and Western blot were carried out during the research.

Results: The expression levels of PLAC2 and CDK2 were both upregulated in OC and they were positively correlated. During the 5-year follow-up, patients with high levels of PLAC2 and CDK2 showed significantly lower overall survival rate. In OC cells, overexpression of PLAC2 resulted in upregulated, while silencing of PLAC2 resulted in downregulated expression of CDK2. Cell proliferation assay showed that overexpression of PLAC2 resulted in increased, while silencing of PLAC2 resulted in decreased proliferation rate of OC cells. In addition, overexpression of CDK2 attenuated the effects of silencing of PLAC2.

Conclusion: PLAC2 positively regulates CDK2 to promote OC cell proliferation.

Keywords: CDK2; PLAC2; ovarian carcinoma; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
PLAC2 and CDK2 were upregulated in OC and positively correlated. The expression levels of PLAC2 and CDK2 measured by RT-qPCR and compared (non-tumor vs OC) by ANOVA (one-way) and Tukey’s test. The expression levels of PLAC2 (A) and CDK2 (B) were significantly higher in OC tissues compared to non-tumor tissues (*p < 0.05). Linear regression showed that PLAC2 and CDK2 were positively correlated in OC tissues (C), but not in non-tumor tissues (D).
Figure 2
Figure 2
High expression levels of PLAC2 and CDK2 predicted poor survival of OC patients. Survival curve comparison showed that high levels of PLAC2 (A) and CDK2 (B) were significantly correlated with low overall survival rate.
Figure 3
Figure 3
PLAC2 positively regulated CDK2 in OC cells. Significantly altered expression of PLAC2 was observed at 24 h after the transfections of PLAC2 expression vector and PLAC2 siRNA compared to C and NC groups (A). PLAC2 overexpression resulted in upregulated (B), while silencing of PLAC2 resulted in downregulated (C) expression of CDK2 (*p < 0.05).
Figure 4
Figure 4
PLAC2 positively regulated OC cell proliferation through cell cycle progression regulation. The effects of overexpression of PLAC2 and CDK2 as well as silencing of PLAC2 on cell cycle progression was analyzed by cell cycle (A). The CCK-8 assay to determine cell viabilities (B). The colony formation was used to determine cell proliferation (C). Data were compared by performing ANOVA (one-way) and Tukey’s test (*p < 0.05).
Figure 5
Figure 5
Silencing of CDK2 ameliorated the severity of ovarian cancer and PLAC2 promoted tumorigenesis in vivo. (A) Measurements of tumor volumes every 1 week for 4 weeks. (B) Representative images of neoplasms from each group of nude mice. (C) Determination of tumor weights. Data are denoted by means ± standard deviation (SD) (*p < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Menon U, Gentry-Maharaj A, Jacobs I. Ovarian cancer screening and mortality. JAMA. 2011;306(14):1544;author reply 1544–1545. doi:10.1001/jama.2011.1461 - DOI - PubMed
    1. Di Lorenzo G, Ricci G, Severini GM, Romano F, Biffi S. Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives. Theranostics. 2018;8(16):4279–4294. doi:10.7150/thno.26345 - DOI - PMC - PubMed
    1. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.006 - DOI - PubMed
    1. Tan J. Targeting resistance. Cell. 2016;166(3):523. doi:10.1016/j.cell.2016.07.017 - DOI - PubMed
    1. Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem. 2010;1(7):209–220. doi:10.4331/wjbc.v1.i7.209 - DOI - PMC - PubMed

Grants and funding

We received the financial support from the Project of Medical and Health Technology Development Program in Shandong province (2017WSA10016).